PHIL Evaluation in the Endovascular Treatment of Intracranial Cerebral ArterioVenous Malformation (cAVM)

Inclusion Criteria: 1. All patients with a ruptured or unruptured and previously endovascularly untreated cAVM that are eligible for endovascular treatment with PHIL® alone or in conjunction with N-Butyl cyanoacrylate glue (NBCA) and/or coils (e.g. if "pressure cooking" technique is needed or used). 2. All patients with a previously endovascularly treated cAVM in which NBCA and/or coils (but not another non-adhesive liquid embolic agent) have been used may be included.\*\* 3. All patients with a remaining cAVM, ruptured or unruptured, that has previously been treated with NS and/or RT may be included. 4. Patient or patient's legally authorized representative has received information about data collection and has signed and dated an Informed Consent Form. (Based on the country's regulation). Exclusion Criteria: 1. cAVM not eligible for endovascular treatment 2. cAVM previously treated with a non-adhesive liquid embolic agent other than PHIL® 3. Treatment requiring the use of any other non-adhesive embolic liquid 4. Patient is allergic to iodine 5. Premature and newborn infant 6. Patient with renal failure or significant liver impairment 7. Patient is participating in another study evaluating other medical devices, other procedures or medications. 8. Any other condition that might prevent patient participation in the study or follow up 9. Patient does not want to and/or refuses to give consent to the collection and processing of data required for centralized monitoring